Wave Life Sciences, Inc. WVE
Wave Life Sciences, Inc. (Nasdaq: WVE) is a cardio-renal-metabolic drug developer. Its lead program, WVE-007, is in Phase 2 for obesity (INHBE GalNAc-siRNA). Its next catalyst on record is WVE-007: Additional INLIGHT data incl. 600 mg SAD cohort (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: WVE-007 — Additional INLIGHT data incl. 600 mg SAD cohort (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| WVE-007 (INLIGHT, Phase 1 SAD + Phase 2a multidose) | obesity | RNA (siRNA/ASO/mRNA) | Phase 2 |
| WVE-006 (RestorAATion-2, Phase 1b/2a) | alpha-1 antitrypsin deficiency | RNA (siRNA/ASO/mRNA) | Phase 1 |
| WVE-N531 (FORWARD-53, Phase 1b/2a extension) | Duchenne muscular dystrophy (exon 53) | oligonucleotide-other | Phase 1 |
| WVE-003 (SELECT-HD Phase 1b/2a completed) | Huntington's disease | oligonucleotide-other | Phase 1 |
| WVE-008 (PNPLA3 I148M AIMer) | PNPLA3 I148M liver disease | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Jul 30, 2026started Dosing underway in the Phase 2a multidose portion of INLIGHT trial of WVE-007 in obesity (BMI 35-50).
Dosing underway in Phase 2a multidose portion of the INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.